ZIM
AMRX icon

Zacks Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Zacks Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,625
Closed -$613K – 712
2025
Q4 		$613K Sell
48,625
-5,926
-11% -$67.8K ﹤0.01% 469
2025
Q3 		$546K Buy
54,551
+8,588
+19% +$77.1K ﹤0.01% 478
2025
Q2 		$372K Sell
45,963
-2,371
-5% -$17.9K ﹤0.01% 524
2025
Q1 		$405K Buy
+48,334
New +$403K ﹤0.01% 509
2021
Q1 		– Sell
-15,835
Closed -$72K – 496
2020
Q4 		$72K Sell
15,835
-107,941
-87% -$478K ﹤0.01% 510
2020
Q3 		$480K Sell
123,776
-3,221
-3% -$13.8K 0.01% 403
2020
Q2 		$605K Buy
+126,997
New +$523K 0.01% 372

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Zacks Investment Management's AMRX Position: Q1 2026 in Review

Zacks Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 48,625 shares — an estimated $613K sold.

Zacks Investment Management first reported a position in AMRX in Q2 2020 and held it in 7 quarters. The position peaked at $613K in Q4 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Zacks Investment Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Zacks Investment Management sold 48,625 Amneal Pharmaceuticals shares in Q1 2026, an estimated $613K.
  • Zacks Investment Management first reported a position in Amneal Pharmaceuticals in Q2 2020 and held it in 7 quarters.
  • Zacks Investment Management's Amneal Pharmaceuticals position peaked at $613K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.